血清miRNA-122-3p在聚乙二醇干扰素-α2b治疗CHB患者中表达的研究  

Expression of serum miRNA-122-3p in patients with CHB treated with PEG-interferon-alpha 2b

作　　者：蒋敏 龚兴 肖新强[1] 张旻[1] Jiang Min;Gong Xing;Xiao Xinqiang;Zhang Min(Department of Infectious diseases,the Second Xiangya Hospital,Central South University,Center for Liver Disease Research,Central South University,Changsha 410011,China;Department of Clinical Laboratory,the Second Xiangya Hospital,Central South University,Changsha 410011,China)

机构地区：[1]中南大学湘雅二医院感染科中南大学肝病研究中心,长沙410011 [2]中南大学湘雅二医院检验科,长沙410011

出　　处：《国际病毒学杂志》2019年第5期293-298,共6页International Journal of Virology

基　　金：国家十三五科技计划子课题(2017ZX10203201);湖南省发改委一般科技项目(2014685)。

摘　　要：目的探究聚乙二醇干扰素-α2b(Peg-IFN-α2b)治疗对血清miRNA-122-3p表达水平的影响.方法收集96例慢性乙型肝炎(chronic hepatitis B,CHB)患者作为治疗组,采用Peg-IFN-α2b治疗48周,停药观察至72周.观察0周、12周、24周、48周、72周血清miRNA-122-3p及HBsAg、HBeAg、HBV-DNA和ALT的变化,同时检测40例正常人的血清miRNA-122-3p作为对照.结果慢性乙型肝炎患者治疗0周及72周血清miRNA-122-3p水平与40个正常人比较,差异均有统计学意义(t=4.524,P<0.01;t=4.565,P<0.01).治疗组0周与72周血清miRNA-122-3p水平无显著差异(t=0.693,P=0.489);72周持续血清HBeAg转换组(SR)与未持续转换组(NSR)比较,HBV-DNA定量(t=-3.809,P<0.01)、HBsAg(t=-9.566,P<0.01)、HBeAg(t=-4.880,P<0.01)及ALT(t=-2.653,P<0.01)差异均有统计学意义,但miRNA-122-3p水平差异无统计学意义(t=-0.998,P=0.321).CHB患者血清miRNA-122-3p含量与HBsAg浓度有相关性(r=0.280,P=0.018),而与HBeAg、HBV-DNA、ALT无关.结论慢性乙型肝炎患者体内血清miRNA-122-3p显著高于正常人,Peg-IFN-α2b治疗可能对血清miRNA-122-3p表达水平无影响,CHB患者血清miRNA-122-3p表达水平与HBsAg有关.Objective To investigate the effect of PEG-interferon-alpha 2b(Peg-IFN-α2b)treatment on serum level of miRNA-122-3p.Methods Ninty-six patients with chronic hepatitis B(CHB)were recruited as the treatment group and were treated with Peg-IFN-α2b for 48 weeks followed by 72 weeks of drug withdrawal for observation.Changes in serum miRNA-122-3p,HBsAg,HBeAg,HBV-DNA and ALT at 0,12,24,48 and 72 weeks were observed.Meanwhile,serum levels of miRNA-122-3p in 40 healthy subjects were analyzed as the control.Results The differences between serum levels of miRNA-122-3p in 40 healthy subjects and in CHB patients at 0 week and 72 weeks of treatment were statistically significant(t=4.524,P<0.01;t=4.565,P<0.01),respectively.There was no statistically significant differences in serum levels of miRNA-122-3p between 0 week and 72 weeks in the treatment group(t=0.693,P=0.489).Statistically significant differences were observed between the persistent HBeAg conversion group(SR)and the non-persistent conversion group(NSR)for 72 weeks in HBV-DNA(t=-3.809,P<0.01),HBsAg(t=-9.566,P<0.01),HBeAg(t=-4.880,P<0.01)and ALT(t=-2.653,P<0.01).There was no statistically significant difference in serum levels of miRNA-122-3p(t=-0.998,P=0.321)between the two groups.Serum levels of miRNA-122-3p levels in CHB patients had a correlation with HBsAg(r=0.28,P=0.018)and no correlation with HBeAg,HBV-DNA and ALT levels.Conclusions Serum level of miRNA-122-3p in CHB patients was significantly higher than that in healthy subjects.Treatment with Peg-IFN-α2b may have no influence on serum miRNA-122-3p expression.The serum level of miRNA-122-3p among CHB patients correlated with HBsAg.

关 键 词：miRNA-122-3p 乙型病毒性肝炎 Peg-IFN-α2b 

分 类 号：R51[医药卫生—内科学]